CLAIMS

1. A pharmaceutical composition or a dietary supplement comprising:

i) an extract or concentrate of Butyrospermum parkii containing at least 5% (w/w) of a Butyrospermum-triterpene fraction comprising:
- at least 2% (w/w) lupeol;
- at least 2% (w/w) α-amyrin and/or β-amyrin;
- at least 2% (w/w) butyrospermol; and
- optionally at least 1% germanicol, dammaradienol, 24-methylene-dammarenol and/or parkeol,

wherein said triterpenes may be in the form of free alcohols or esters thereof, especially cinnamic acid, acetic acid or fatty acid esters; and

ii) optionally a pharmaceutically acceptable carrier.

2. A pharmaceutical composition or a dietary supplement comprising:

i) an extract or concentrate of Butyrospermum parkii containing at least 5% (w/w) of a Butyrospermum-triterpene fraction comprising:
- 10-40% (w/w) lupeol;
- 10-40% (w/w) α-amyrin and/or β-amyrin;
- 10-40% (w/w) butyrospermol; and
- optionally 2-30% germanicol, dammaradienol, 24-methylene-dammarenol and/or parkeol,

wherein said triterpenes may be in the form of free alcohols or esters thereof, especially cinnamic acid, acetic acid or fatty acid esters; and

ii) optionally a pharmaceutically acceptable carrier.

3. A pharmaceutical composition or dietary supplement according to claim 1 or 2, where the extract or concentrate of Butyrospermum parkii further comprises a sterol fraction comprising at least one sterol selected from the group consisting of stigmasterol, ava-

nasterol, 24-methyl-cholest-7-enol, karitesterol A, karitesterol B and α-spinasterol, wherein said sterols may be in the form of free alcohols or esters thereof, especially cinnamic acid, acetic acid or fatty acid esters.

4. A pharmaceutical composition or dietary supplement according to ~~any of the preceding claims~~ claim 1, wherein the Butyrospermum-triterpene fraction optionally together with the sterol fraction comprises up to 100% (w/w) of the extract or concentrate of Butyrospermum parkii.

5. A pharmaceutical composition or dietary supplement according to any of claims 3 or 4, wherein the ratio between the Butyrospermum-triterpene fraction and the sterol fraction is in the range of 1:100 to 500:1 (w/w).

6. A pharmaceutical composition or dietary supplement according to ~~any of the preceding claims~~ claim 1, which further comprises an extract of Calendula officinalis.

7. A pharmaceutical composition according to ~~any of the preceding claims~~ claim 1 for systemic administration.

8. A pharmaceutical composition according to ~~any of claims 1 to 6~~ claim 1 for topical administration, wherein the pharmaceutical composition contains at least 5% (w/w) of the Butyrospermum-triterpene fraction.

9. A pharmaceutical composition according to claim 8, wherein the pharmaceutical composition is formulated as a fluid, ointment, gel, liniment, emulsion (e.g. cream or lotion) or spray (e.g. aerosol).

10. The use of a composition according to ~~any of claims 1 to 9~~ claim 1 for the preparation of a medicament or a dietary supplement for immunomodulation in a mammal.

11. The use of a composition according to ~~any of claims 1 to 9~~ claim 1 for the preparation of a medicament or a dietary supplement for the suppression of hypersensitivity and/or inflammatory reaction in a mammal.

12. The use of a composition according to claim 11 for the preparation of a medicament for the treatment or prevention of inflammation or hypersensitivity of the skin or mucous membranes in a mammal.

13. The use according to claim 11 or 12 for the preparation of a medicament or a dietary supplement for the treatment or prevention of autoimmune disease and/or chronic inflammatory disease in a mammal.

14. The use according to claim 13 for the preparation of a medicament or a dietary supplement for the treatment or prevention of psoriasis, atopic dermatitis, contact dermatitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis or osteoarthritis in a mammal.

15. The use of a composition according to ~~any of claims 1 to 9~~ claim 1 for the preparation of a medicament or a dietary supplement for the alleviation of pain in a mammal.

16. The use of a composition according to ~~any of claims 1 to 9~~ claim 1 for the preparation of a medicament or a dietary supplement for the treatment or prevention of prostatitis and/or benign prostatic hypertrophy.

17. A method for the treatment or prevention of hypersensitivity or inflammation in a mammal, characterised by administering a composition according to ~~any of claims 1 to 9~~ claim 1 to said mammal.

18. A method for the treatment or prevention of inflammation or hypersensitivity of the skin or mucous membranes of a mammal, characterised by administering a composition according to ~~any of claims 1 to 9~~ claim 1 to said mammal.

19. A method for the treatment or prevention of an autoimmune disorder and/or a chronic inflammatory disorder in a mammal, characterised by administering a mixture according to ~~any of claims 1 to 9~~ claim 1 to said mammal.

20. A method for the treatment or prevention of psoriasis, atopic eczema, contact dermatitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis and/or osteoarthritis in a

mammal, characterised by administering a mixture according to ~~any of claims 1 to 9~~ [claim 1] to said mammal.

21. A method for the treatment or prevention of pain in a mammal, characterised by administering a mixture according to ~~any of claims 1 to 9~~ [claim 1] to said mammal.

22. A method for the treatment or prevention of prostatitis or benign prostatic hypertrophy in a mammal, characterised by administering a mixture according to ~~any of claims 1 to 9~~ [claim 1] to said mammal.

23. A method for the preparation of a composition according to ~~any of claims 1 to 9~~ [claim 1], characterised by obtaining an extract or a concentrate of *Butyrospermum parkii*, said extract or concentrate containing at least 5% (w/w) of a Butyrospermum-triterpene fraction comprising:

- at least 2% (w/w) lupeol;
- at least 2% (w/w) α-amyrin and/or β-amyrin;
- at least 2% (w/w) butyrospermol; and
- optionally at least 1% germanicol, dammaradienol, 24-methylene-dammarenol and/or parkeol,

wherein said triterpenes may be in the form of free alcohols or esters thereof, especially cinnamic acid, acetic acid or fatty acid esters; and

24. A method according to claim 22, wherein the extract or concentrate of Butyrospermum parkii further comprises a sterol fraction comprising at least one sterol selected from the group consisting of stigmasterol, avanasterol, 24-methyl-cholest-7-enol, karitesterol A, karitesterol B and α-spinasterol, wherein said sterols may be in the form of free alcohols or esters thereof, especially cinnamic acid, acetic acid or fatty acid esters.

25. A method according to claim 22 or 23, wherein said extract or concentrate of Butyrospermum parkii is further mixed with a pharmaceutically acceptable carrier.